Endo Pharmaceuticals Inc, Malvern, Pa.
Endo Pharmaceuticals Inc, Malvern, Pa.
J Allergy Clin Immunol. 2014 Apr;133(4):1075-83. doi: 10.1016/j.jaci.2013.10.029. Epub 2013 Dec 14.
Anaphylaxis is a serious allergic reaction that can cause death; however, the actual risk of death is unclear.
We sought to estimate the case fatality rate among hospitalizations or emergency department (ED) presentations for anaphylaxis and the mortality rate associated with anaphylaxis for the general population.
This was a population-based epidemiologic study using 3 national databases: the Nationwide Inpatient Sample (NIS; 1999-2009), the Nationwide Emergency Department Sample (NEDS; 2006-2009), and Multiple Cause of Death Data (MCDD; 1999-2009). Sources for these databases are hospital and ED discharge records and death certificates, respectively.
Case fatality rates were between 0.25% and 0.33% among hospitalizations or ED presentations with anaphylaxis as the principal diagnosis (NIS+NEDS, 2006-2009). These rates represent 63 to 99 deaths per year in the United States, approximately 77% of which occurred in hospitalized patients. The rate of anaphylaxis-related hospitalizations increased from 21.0 to 25.1 per million population between 1999 and 2009 (annual percentage change, 2.23%; 95% CI, 1.52% to 2.94%), contrasting with a decreasing case fatality rate among hospitalizations (annual percentage change, -2.35%; 95% CI, -4.98% to 0.34%). Overall mortality rates ranged from 0.63 to 0.76 per million population (186-225 deaths per year, MCDD) and appeared stable in the last decade (annual percentage change, -0.31%; 95% CI, -1.54% to 0.93%).
From 2006 to 2009, the overwhelming majority of hospitalizations or ED presentations for anaphylaxis did not result in death, with an average case fatality rate of 0.3%. Anaphylaxis-related hospitalizations increased steadily in the last decade (1999-2009), but this increase was offset by the decreasing case fatality rate among those hospitalized; both inpatient and overall mortality rates associated with anaphylaxis appeared stable and were well under 1 per million population. Although anaphylactic reactions are potentially life-threatening, the probability of dying is actually very low. With the prevalence of anaphylaxis on the increase, practitioners need to stay vigilant and follow the treatment guidelines to further reduce anaphylaxis-related deaths.
过敏反应是一种严重的过敏反应,可能导致死亡;然而,实际死亡风险尚不清楚。
我们旨在评估因过敏反应住院或到急诊就诊的病死率,以及一般人群中因过敏反应导致的死亡率。
这是一项基于人群的流行病学研究,使用了 3 个国家数据库:全国住院患者样本(NIS;1999-2009 年)、全国急诊患者样本(NEDS;2006-2009 年)和死因多重原因数据(MCDD;1999-2009 年)。这些数据库的来源分别是医院和急诊部门的出院记录和死亡证明。
作为主要诊断的过敏反应住院或急诊就诊的病死率在 0.25%至 0.33%之间(NIS+NEDS,2006-2009 年)。这些比率代表美国每年约有 63 至 99 人死亡,其中约 77%发生在住院患者中。1999 年至 2009 年间,因过敏反应导致的住院率从 21.0 增加到 25.1/百万人(年变化百分比,2.23%;95%CI,1.52%至 2.94%),而住院患者的病死率呈下降趋势(年变化百分比,-2.35%;95%CI,-4.98%至 0.34%)。总体死亡率范围为 0.63 至 0.76/百万人(每年 186-225 人死亡,MCDD),在过去十年中似乎保持稳定(年变化百分比,-0.31%;95%CI,-1.54%至 0.93%)。
2006 年至 2009 年,因过敏反应住院或到急诊就诊的患者绝大多数未死亡,平均病死率为 0.3%。过去十年中,因过敏反应导致的住院率稳步上升(1999-2009 年),但这一增长被住院患者病死率的下降所抵消;与过敏反应相关的住院和总体死亡率似乎保持稳定,均远低于每百万人 1 人。尽管过敏反应可能有生命危险,但实际上死亡的可能性非常低。随着过敏反应的患病率不断增加,医生需要保持警惕并遵循治疗指南,以进一步降低与过敏反应相关的死亡人数。